Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 1/20 | 0.32 |
| ▸ | OTUD7B | Q6GQQ9 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.32 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.32 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.32 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 2/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | APEX1 | P27695 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6731350 | 0.89 | GRIN1 (0.35) | KDM4EALDH1A1CYP3A4GABRB3OPRD1 | |
| SCHEMBL27507479 | 0.82 | CYP19A1 (0.33) | CYP19A1OTUD7B | |
| SCHEMBL26442036 | 0.74 | CRBN (0.43) | CYP19A1CYP3A4TSHRNPSR1 | |
| SCHEMBL11886192 | 0.70 | OTUD7B (0.32) | OTUD7B | |
| SCHEMBL1605832 | 0.70 | AR (0.36) | CYP19A1OTUD7BKDM4ETSHRNPSR1 | |
| SCHEMBL13081612 | 0.69 | TSHR (0.50) | CYP19A1KDM4EALDH1A1CYP3A4GABRB3 | |
| SCHEMBL23836081 | 0.68 | OTUD7B (0.31) | OTUD7B | |
| SCHEMBL7433600 | 0.68 | OTUD7B (0.31) | OTUD7B | |
| SCHEMBL17172987 | 0.68 | OTUD7B (0.31) | OTUD7B | |
| SCHEMBL25134507 | 0.68 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2019228252-A1 | HIGHLY ACTIVE CSF1R INHIBITOR COMPOUND | 杭州阿诺生物医药科技有限公司 (CN) | 2019-12-05 | — | — | WO | disclosed |
| US-10428070-B2 | Hepatitis B antiviral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2019-10-01 | — | — | US | disclosed |
| US-20190177320-A1 | HEPATITIS B ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. | 2019-06-13 | — | — | US | disclosed |
| US-6680331-B2 | ADMINISTERING DIETHYL LACTAMS SUCH AS 3,3-DIETHYL-2-PYRROLIDINONE FOR INDUCING ANESTHESIA OR CONSCIOUS SEDATION | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2004-01-20 | — | — | US | disclosed |
| US-20030078283-A1 | Lactam and thiolactam derivatives as anesthetic and conscious sedation agents | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2003-04-24 | — | — | US | disclosed |
| WO-2003007940-A1 | LACTAM AND THIOLACTAM DERIVATIVES AS ANESTHETIC AND CONSCIOUS SEDATION AGENTS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2003-01-30 | — | — | WO | disclosed |
| US-6066666-A | OPTIONALLY N-SUBSTITUTED 3-MONO- AND DI-SUBSTITUTED 2-PYRROLIDINONES AND THIOLACTAM ANALOGS; TREAT SEIZURES, ANXIETY, AND ENHANCING 4-AMINOBUTYRIC ACID (GABA)-INDUCED CHLORIDE CURRENTS AT GABA RECEPTOR/IONOPHORE COMPLEX | WASHINGTON UNIVERSITY (US) | 2000-05-23 | — | — | US | disclosed |
| US-5776959-A | Anticonvulsant and anxiolytic lactam and thiolactam derivatives | WASHINGTON UNIVERSITY (US) | 1998-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190177320-A1 | HEPATITIS B ANTIVIRAL AGENTS | HAVCR2, SLC10A1, HDGF | CYP19A1 2289/4885OTUD7B 662/4885KDM4E 2448/4885 |
| US-10428070-B2 | Hepatitis B antiviral agents | HAVCR2, SLC10A1, HDGF | CYP19A1 2289/4885OTUD7B 662/4885KDM4E 2448/4885 |
| US-20030078283-A1 | Lactam and thiolactam derivatives as anesthetic and conscious sedation agents | GABRD, GABRE, CCT8 | CYP19A1 3413/4885OTUD7B 792/4885KDM4E 600/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.